Q-omics provides the consensus-scored DLX2-DT profile across patient tissues and cancer cell-line models. DLX2-DT expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DLX2-DT is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, DLX2-DT RNA expression shows 9,825 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where DLX2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLX2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLX2-DT survival associations across molecular data types. DLX2-DT RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLX2-DT RNA expression–survival associations across cancer types. High DLX2-DT expression shows unfavorable associations in ACC, KIRC, KICH, LUAD, MESO and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DLX2-DT RNA expression.
This table summarizes DLX2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for DLX2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLX2-DT shows higher tumor expression in HNSC, LUSC, BRCA, LIHC, BLCA and LUAD. The HNSC box plot shows higher DLX2-DT RNA expression in tumor versus normal tissue (log2 FC = +0.612, t-test p < 0.001).
This table shows molecular features associated with DLX2-DT in patient tissues and cancer cell lines. In patient samples, DLX2-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
